Regulatory scientific advice in drug development: does company size make a difference?

M. Putzeist; A.K. Mantel-Teeuwisse; C.C. Gispen-de Wied; A.W. Hoes; H.G.M. Leufkens

Regulatory scientific advice in drug development: does company size make a difference?

M. Putzeist, A.K. Mantel-Teeuwisse, C.C. Gispen-de Wied, A.W. Hoes, H.G.M. Leufkens

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	157-164
Number of pages	8
Journal	European Journal of Clinical Pharmacology
Volume	67
Publication status	Published - 2011

Keywords

Econometric and Statistical Methods: General
Epidemiology
Farmacie(FARM)
Geneeskunde(GENK)
Medical sciences
Bescherming en bevordering van de menselijke gezondheid
Biomedische technologie en medicijnen
Ziekenhuisstructuur en organisatie van de gezondheidszorg
Public Health

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/21049297

Cite this

@article{b1f370bce0064f00a031261edaa94039,

title = "Regulatory scientific advice in drug development: does company size make a difference?",

keywords = "Econometric and Statistical Methods: General, Epidemiology, Farmacie(FARM), Geneeskunde(GENK), Medical sciences, Bescherming en bevordering van de menselijke gezondheid, Biomedische technologie en medicijnen, Ziekenhuisstructuur en organisatie van de gezondheidszorg, Public Health",

author = "M. Putzeist and A.K. Mantel-Teeuwisse and {Gispen-de Wied}, C.C. and A.W. Hoes and H.G.M. Leufkens",

year = "2011",

language = "English",

volume = "67",

pages = "157--164",

journal = "European Journal of Clinical Pharmacology",